ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD5 CAR NK cells

Its studies are mostly in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, led by Chongqing Precision Biotech.

Furthest: phase 1, since Mar 27, 20251 company-led study, 1 open or runningNext primary completion: Mar 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Precision Biotech11 open or runningphase 1since Mar 27, 2025Mar 27, 2025Mar 31, 2027phase 1 · NCT06909474

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2025First study: phase 1 study in Precursor T-Cell Lymphoblastic Leukemia-LymphomaFirst studyNCT06909474 · 15 planned · China

Ahead

  1. Mar 31, 2027Primary completion: phase 1 study in Precursor T-Cell Lymphoblastic Leukemia-LymphomaNCT06909474

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06909474Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China1RecruitingMar 31, 202715

How it is read

Names in the registry

  • “Anti-CD5 CAR NK cells”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.